总部位于巴黎的公司Orakl Oncology在A轮融资中获得了3400万美元。该公司计划利用这笔资金开发人工智能驱动的虚拟癌症患者。这些模型旨在加速临床试验前的药物测试和疗效预测。 AI
影响 这项融资可以通过更有效地测试潜在疗法来加速药物发现和开发。
排序理由 一家专注于人工智能的生物技术公司的重大融资轮次。
在 Mastodon — mastodon.social 阅读 →
AI 生成摘要 · Google Gemini · 来自 1 个来源。 我们如何撰写摘要 →
Orakl Oncology 融资 3400 万美元用于开发人工智能驱动的虚拟癌症患者
本文如何被排名
- Signal score
- 14 / 100
- Composite score across the factors below. Higher = stronger signal that this story matters right now.
- Newsworthiness bucket
- Research
- 一家专注于人工智能的生物技术公司的重大融资轮次。
- Source corroboration
- Single-source cluster
- Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
- Topics
- funding, product, other
- Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
- AI-industry relevance
- High
- Clearly on-topic for AI-industry coverage.
- Story freshness
- Breaking (< 6h)
- Fresh story with cross-source coverage still developing. Ranking may shift as more sources report.
完整方法见我们的编辑标准。
报道来源 [1]
-
总部位于巴黎的Orakl Oncology已完成3400万美元A轮融资，将用于构建AI驱动的虚拟癌症患者模型，用于药物测试和预测其有效性
Paris-based Orakl Oncology has raised a 34M USD Series A to build AI-powered virtual cancer patients, models used to test drugs and predict their efficiency before they reach clinical trials. Swedish investor Norrsken and Paris-based VC Singular co-led the round. https:// sifted.…